top of page

Occam Places Jorge Bartolome as CEO at Areteia Therapeutics

Areteia Therapeutics, a private clinical stage biotech that just raised $350M in a Series A led by Bain Capital, is the product of a collaboration between Clive Meanwell’s Population Health Partners and Knopp Biosciences. The recent robust financing round will be used to advance its lead candidate, dexpramipexole, a small molecule in phase 3 development, one holding out great promise as the first oral therapy for asthma. If successful, this compound represents a potential game changing treatment for an ubiquitous and difficult to treat chronic condition.

Jorge enters the fray at a critical point in the company’s evolution. He brings powerful domain expertise and decades of commercial leadership to the party. Previously, Bartolome served as President of Canada for Janssen and, prior to that, as SVP of the US Respiratory Business Unit of GSK.

See Full Press Release:

bottom of page